Clobetasol propionate with neomycin and nystatin
Brand names: Dermovate-NN
A topical preparation combining the very potent corticosteroid clobetasol propionate with the aminoglycoside antibacterial neomycin and the antifungal nystatin, used for short-term treatment of severe inflammatory skin disorders complicated by bacterial and/or candidal infection.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Clobetasol suppresses cutaneous inflammation via glucocorticoid receptors, neomycin is bactericidal by inhibiting bacterial protein synthesis, and nystatin binds fungal ergosterol to kill Candida.
Prescribing in practice
- Combining a very potent steroid with an antibacterial and antifungal risks both steroid-induced skin atrophy/systemic absorption and neomycin contact sensitisation, so it should be reserved for short courses where infection genuinely complicates inflammation.
- Avoid prolonged or large-area use, and limit application near the ears as topical neomycin carries a theoretical risk of ototoxicity if absorbed through broken skin or large areas.
- Avoid use on the face and flexures where possible and do not apply to extensive raw or denuded skin.
Monitoring
Review the treated skin regularly for atrophy, sensitisation and treatment response, and stop if the infection or inflammation fails to improve.
Counselling the patient
- Apply thinly to affected areas only and use for no longer than directed.
- Stop and seek advice if the rash worsens or new redness, itch or swelling develops, which may indicate allergy to the antibiotic.
Evidence & guidelines
Combined potent steroid-antimicrobial preparations are recommended only for short-term use in infected inflammatory dermatoses; neomycin sensitisation is a well-recognised limitation.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Steroid Dose Equivalence · Medications
- Adrenal Crisis Risk Score · Adrenal Disorders
- Lille Model (Steroid Response in Alcoholic Hepatitis) · Alcoholic Liver Disease
- Ho Index for Predicting Response to Medical Therapy in IBD · Inflammatory Bowel Disease
- Steroid Conversion Calculator · Drug Dosing
- FAST Exam Protocol — Focused Assessment with Sonography in Trauma · Trauma
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD